downgraded at Citigroup to Neutral from Buy, Citigroup said. $46 price target. Catalysts playing out and risk/reward more balanced.
downgraded at UBS to Neutral from Buy, UBS said. $37 price target. Moving to sidelines following ESRX settlement.
STOCK COMMENTS / EPS CHANGES
target raised at Jefferies. Shares of ATHN now seen reaching $85, Jefferies said. Recent HMA win validates ability to compete. Hold rating.
numbers raised at UBS. Shares of BHI now seen reaching $65, UBS said. Estimates also increased on solid N. Am results. Buy rating.
numbers cut at Citigroup. Shares of CME now seen reaching $58, Citigroup said. Estimates also lowered as volume environment remains challenging. Buy rating.
numbers lowered at UBS. Shares of COH now seen reaching $63, UBS said. Estimates also lowered on weakening US growth outlook. Neutral rating.
estimates, target cut at Keybanc. Shares of CYT now seen reaching $80, according to Keybanc. Estimates also reduced, given the sale of the coatings resin business. Buy rating.
numbers reduced at Credit Suisse. FHN estimates were cut through 2014, Credit Suisse said. Company is seeing lower fee income and higher costs. Outperform rating and new $9 price target.
estimates lowered at Morgan Stanley through 2014, Morgan Stanley said. Backlog is flattening. Equal-weight rating and $22 price target.
estimates raised at Oppenheimer through 2013, Oppenheimer said. Updating model for Motorola Mobility acquisition. Outperform rating.
numbers reduced at Morgan Stanley. JCI estimates were cut through 2014, Morgan Stanley said. Company lacks near-term catalysts. Overweight rating and new $38 price target.
estimates, target cut at BofA/Merrill. Shares of MAN now seen reaching $45, according to Bank of America/Merrill Lynch said. Estimates also reduced, given slower growth in Europe. Outperform rating.
cut from Conviction Buy List at Goldman. RevPAR growth is below the broader industry.
added to Conviction Buy List at Goldman. $50 price target. Strong housing recovery appears to be starting.
numbers increased at Goldman. ONXX estimates were raised through 2015, Goldman Sachs said. Kyprolis is coming to market sooner than expected and should have better pricing. Buy rating and new $85 price target.
Philip Morris International
numbers raised at Jefferies. Shares of PM now seen reaching $92, Jefferies said. Estimates also raised on solid earnings. Hold rating.
estimates, target raised at Credit Suisse. Shares of STI now seen reaching $27, according to Credit Suisse. Estimates also increased, as the company is seeing higher mortgage banking and trading revenue. Outperform rating.
estimates, target reduced at Morgan Stanley. XRX estimates were cut through 2013, given a weaker macro outlook. Neutral rating and new $8 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on